Arax Advisory Partners’s Dyne Therapeutics DYN Stock Holding History

Arax Advisory Partners’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-18	Closed	-$352	–	3946
2025 Q4	$352	Sell	18 -465	-96%	-$8.81K	﹤0.01%	3655
2025 Q3	$6.11K	Buy	483 +253	+110%	+$2.89K	﹤0.01%	2805
2025 Q2	$2.19K	Hold	230	–	–	﹤0.01%	2545
2025 Q1	$2.41K	Sell	230 -20	-8%	-$286	﹤0.01%	2015
2024 Q4	$5.89K	Hold	250	–	–	﹤0.01%	1684
2024 Q3	$8.98K	Hold	250	–	–	﹤0.01%	1468
2024 Q2	$8.82K	Buy	250 +20	+9%	+$581	﹤0.01%	1329
2024 Q1	$6.53K	Hold	230	–	–	﹤0.01%	858
2023 Q4	$3.06K	Buy	+230	New	+$2.25K	﹤0.01%	966

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Arax Advisory Partners's DYN Position: Q1 2026 in Review

Arax Advisory Partners sold out of Dyne Therapeutics (DYN) in Q1 2026, closing a stake of 18 shares — an estimated $352 sold.

Arax Advisory Partners first reported a position in DYN in Q4 2023 and held it in 9 quarters. The position peaked at $8.98K in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Arax Advisory Partners reported no remaining Dyne Therapeutics position as of Q1 2026 after selling out during the quarter.
Arax Advisory Partners sold 18 Dyne Therapeutics shares in Q1 2026, an estimated $352.
Arax Advisory Partners first reported a position in Dyne Therapeutics in Q4 2023 and held it in 9 quarters.
Arax Advisory Partners's Dyne Therapeutics position peaked at $8.98K in Q3 2024.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.